See: Template talk:Sticky header#Borders on sticky headers in Firefox tables

Template:Header test

Multi-row header edit

Without sticky template

rowspan and colspan
Name Data columns are below
1 2 3
Name1 1-1 2-1 3-1
Name2 1-2 2-2 3-2
Name3 1-3 2-3 3-3
Name4 1-4 2-4 3-4
Name5 1-5 2-5 3-5
Name6 1-6 2-6 3-6

With sticky template Template:Header test

Wiki source excerpt:

{{mw-datatable}}{{header test}}{{sort under}}
{| class="wikitable sortable mw-datatable sort-under sticky-header" 
|+ rowspan and colspan
|-
! rowspan=2 | Name
! colspan=3 style=max-width:8em | Data columns are below
|- 
! 1
! 2
! 3
|-
...


Wiki source. Full table:

{{mw-datatable}}{{header test}}{{sort under}}
{| class="wikitable sortable mw-datatable sort-under sticky-header" 
|+ rowspan and colspan
|-
! rowspan=2 | Name
! colspan=3 style=max-width:8em | Data columns are below
|- 
! 1
! 2
! 3
|-
| Name1 || 1-1 || 2-1 || 3-1
|-
| Name2 || 1-2 || 2-2 || 3-2
|-
| Name3 || 1-3 || 2-3 || 3-3
|-
| Name4 || 1-4 || 2-4 || 3-4
|-
| Name5 || 1-5 || 2-5 || 3-5
|-
| Name6 || 1-6 || 2-6 || 3-6
|}

Single-row header edit

Template:Header test

COVID-19 vaccines authorized for emergency use or approved for full use
Common name Type (technology) Country of origin First authorization Notes
Authorized in more than 10 countries
Oxford–AstraZeneca Adenovirus vector United Kingdom, Sweden December 2020
Pfizer–BioNTech RNA Germany, United States December 2020 Both original and Omicron variant versions
Janssen (Johnson & Johnson) Adenovirus vector United States, Netherlands February 2021
Moderna RNA United States December 2020 Both original and Omicron variant versions
Sinopharm BIBP Inactivated China July 2020
Sputnik V Adenovirus vector Russia August 2020
CoronaVac Inactivated China August 2020 Low efficacy in replication studies and with certain variants
Novavax Subunit/virus-like particle United States December 2021 A "recombinant nanoparticle vaccine"[1]
Covaxin Inactivated India January 2021
Valneva Inactivated France, Austria April 2022
Sanofi–GSK Subunit France, United Kingdom November 2022 Based on Beta variant
Sputnik Light Adenovirus vector Russia May 2021
Authorized in 2–10 countries
Convidecia Adenovirus vector China June 2020
Sinopharm WIBP Inactivated China February 2021 Lower efficacy
Abdala Subunit Cuba July 2021
EpiVacCorona Subunit Russia October 2020
Zifivax Subunit China March 2021
Soberana 02 Subunit Cuba, Iran June 2021
CoviVac Inactivated Russia February 2021
Medigen Subunit Taiwan July 2021
QazCovid-in Inactivated Kazakhstan April 2021
Minhai Inactivated China May 2021 Undergoing clinical trials
COVIran Barekat Inactivated Iran June 2021
Soberana Plus Subunit Cuba August 2021
Corbevax Subunit India, United States December 2021
Authorized in 1 country
Chinese Academy of Medical Sciences Inactivated China June 2021
ZyCoV-D DNA India August 2021
FAKHRAVAC Inactivated Iran September 2021
COVAX-19 Subunit Australia, Iran October 2021
Razi Cov Pars Subunit Iran October 2021
Turkovac Inactivated Turkey December 2021
Sinopharm CNBG Subunit China December 2021 Based on original, Beta, and Kappa variants
CoVLP Virus-like particle Canada, United Kingdom February 2022
Noora Subunit Iran March 2022
Skycovione Subunit South Korea June 2022
Walvax RNA China September 2022
iNCOVACC Adenovirus vector India September 2022 Nasal vaccine
V-01 Subunit China September 2022
Gemcovac RNA India October 2022 Self-amplifying RNA vaccine
IndoVac Subunit Indonesia October 2022
  1. ^ "Urgent global health needs addressed by Novavax". Novavax. Archived from the original on 12 May 2021. Retrieved 30 January 2021.